Thermo Fisher Scientific and Innoforce Partner in China
Published on:
Thermo Fisher Scientific Inc. and Innoforce announced they have signed a joint venture agreement to establish a new pharma services facility in Hangzhou, China, for integrated biologics and steriles drug development and manufacturing. The new facility is expected to be completed in 2022 and will become part of Thermo Fisher's global pharma services network.
"Our agreement with Innoforce will provide critical support in helping to meet the high demand for biologics in China," said Michel Lagarde, executive vice president, Thermo Fisher Scientific. "The addition of the Hangzhou site will expand our existing global network and provide drug development and manufacturing services for customers in China, as well as for global customers seeking capabilities in the region."
